MY-875

Item no.	HY-150761-25mg
Manufacturer	MedChem Express
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.44
Formula	C21H25NO6
Citations	[1]Jian Song, et al. Discovery of N-benzylarylamide derivatives as novel tubulin polymerization inhibitors capable of activating the Hippo pathway. Eur J Med Chem. 2022 Jul 7;240:114583.
Smiles	COC1=CC(N(C(/C=C/C)=O)CC2=CC(O)=C(OC)C=C2)=CC(OC)=C1OC
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Microtubule/Tubulin
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	387.43
Product Description	MY-875 is a competitive microtubulin polymerization inhibitor with an IC50 value of 0.92 μM. MY-875 inhibits microtubulin polymerization by targeting colchicine binding sites and activates the Hippo pathway. MY-875 induces apoptosis and has anticancer activity[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO : ≥ 250 mg/mL
Manufacturer - Pathway	Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-150761-25mg-safety-datasheet.pdf